The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Our portfolio includes biosimilars for immunology, oncology, and ophthalmology indications, a nephrology product line, and a Parkinson’s franchise. Our specialty medicines account for approximately 20% of STADA’s sales, which reached an impressive EUR 3.80 billion in 2022, marking an 11% increase from the previous year.
As Europe’s fourth-largest supplier of consumer healthcare and generic medicines by sales, we are proud to serve patients in approximately 120 countries worldwide. Our team of 13,183 employees is dedicated to delivering innovative solutions that meet the evolving needs of patients and healthcare providers. Our Headquarters is located in Bad Vilbel, Germany.
For more information, please visit: www.stada.com: Specialty Pharmaceuticals | STADA